|
| NCT identifier | Setting | Phase | Study interventions | Number of patients | Primary endpoint |
|
| Checkpoint inhibitors |
| NCT02689284 | Metastatic HER2+ GC/GEJC | Ib/II | Margetuximab+ pembrolizumab | 52 | MTD and MAD for margetuximab; duration of response; 12-month ORR |
| NCT02563548 | Metastatic GC after 1st line | Ib | PEGPH20 +pembrolizumab | 81 | DLT; 18-month ORR |
| NCT02443324 | Metastatic GC/GEJC and other tumours | I | Ramucirumab + pembrolizumab | 155 | DLT |
| NCT02589496 | Metastatic GC/GEJC after first line | II | Pembrolizumab | 40 | 2-year RR |
| NCT02901301 | First-line HER2 + GC | Ib/II | Pembrolizumab + trastuzumab + capecitabine + cisplatin | 49 | RP2D; 6-week ORR |
| NCT02954536 | First-line HER2+ GC/GEJC/EC | II | Pembrolizumab + trastuzumab + capecitabine + cisplatin | 37 | 6-month PFS |
| NCT02318901 | Unresectable HER2 + GC/GEJC | II | Pembrolizumab + ado-trastuzumab emtansine | 90 | RP2D |
| NCT02559687 | EC (adenocarcinoma or squamous cell)/GEJC after 2nd line | II | Pembrolizumab | 100 | 2-year ORR |
| NCT02494583 | First-line GC/GEJC | III (random) | Pembrolizumab versus pembrolizumab + cisplatin + 5-fluorouracil or capecitabine versus placebo + cisplatin + 5-FU or capecitabine | 750 | 44-month PFS and OS |
| NCT02370498 | Second-line GC/GEJC | III (random) | Pembrolizumab versus paclitaxel | 720 | PFS, OS |
| NCT02564263 | EC (adenocarcinoma or squamous cell) /GEJC after 1st line | III (random) | Pembrolizumab versus investigator's choice of standard therapy (paclitaxel, docetaxel, or irinotecan) | 600 | 3-year PFS and OS |
| NCT02872116 | Unresectable GC/GEJC | III (random) | Nivolumab + ipilimumab versus nivolumab + oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine | 1266 | 40-month OS in patients PD-L1 + |
| NCT02864381 | Metastatic GC/GEJC | II (random) | GS-5745 + nivolumab versus nivolumab alone | 120 | 2-year ORR |
| NCT02340975 | Pretreated metastatic/GC/GEJC | Ib/II (random) | MEDI4736 + tremelimumab versus MEDI4736 versus tremelimumab | 135 | Phase Ib: DTL,
Phase II: ORR and 6-month PFS |
| NCT02625623 | 3rd-line GC/GEJC | III (random) | Avelumab+ BSC versus chemotherapy (paclitaxel or irinotecan)+BSC or BSC alone | 330 | 2-year OS |
| NCT02625610 | 1st-line GC/GEJC | III (random) | Maintenance with avelumab versus continuation of 1st-line chemotherapy | 666 | 3-year OS and PFS |
|
| Immunotherapy + radiotherapy |
| NCT02642809 | 1st-line EC | I | Pembrolizumab + brachytherapy | 15 | Tolerability and toxicity |
| NCT02830594 | Pretreated EC/GC(GEJC | II | Pembrolizumab + external beam palliative radiation therapy | 14 | Biomarkers |
| NCT02735239 | Metastatic EC | I/II | Durvalumab + oxaliplatin/capecitabine | 75 | AE, DLT, laboratory evaluations |
| Vaccines | | | | | |
| NCT02276300 | Metastatic HER 2 + GC | I | HER2-derived peptide vaccination | 12 | Safety and tolerability |
| NCT02317471 | Stage III gastric cancer | I/II | Vaccination with autologous tumour derived heat shock protein gp96 | 45 | DFS |
| NCT02795988 | Metastatic HER 2 + GC/GEJC | Ib/II | IMU-131 HER2/Neu peptide vaccine+ cisplatin and either 5-FU or capecitabine chemotherapy | 18 | RP2D, AE |
| Cytokines | | | | | |
| NCT01691664 | Locally advanced EC | NS (random) | Radiation therapy alone or with DC-CIK cellular therapy | 40 | DFS |
| NCT01691625 | Locally advanced EC | NS (random) | Concurrent chemoradiation with or without DC-CIK | 50 | Quality of life |
| NCT02504229 | Metastatic refractory GC | II
(random) | Chemotherapy with or without DC-CIK | 80 | PFS |
| NCT01783951 | Metastatic refractory GC | I/II | S-1 with or without DC-CIK | 30 | PFS |
|
| CAR-T cells |
| NCT02713984 | Metastatic refractory HER 2 + GC | I/II | Anti-HER2 CAR-T cells | 60 | Toxicity |
| NCT02725125 | Metastatic refractory GC | I/II | EPCAM-targeted CAR-T cells | 19 | DCR |
| NCT02617134 | Metastatic refractory MUC1+ GC | I/II | Anti-MUC1 CAR-T cells | 20 | Toxicity |
| NCT02349724 | Metastatic refractory CEA+ GC | I | Anti-CEACAR-T cells | 75 | Toxicity |
| NCT02862028 | Metastatic refractory EGFR+ GC | I/II | Anti-PD-1CAR-T cells | 20 | ORR, DCR, OS, PFS |
| NCT03013712 | Metastatic refractory EpCAM+ GC/EC | I/II | Anti-EpCAMCAR-T cells | 60 | Toxicity |
|
